Drugs / ENERGI-F703
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04078555 | Jul 2022 → Mar 2025 | ulcer of lower limbs | Energenesis Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05930210 | May 2023 → Dec 2025 overdue | diabetes mellitus, ulcer of lower limbs | Energenesis Biomedical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENERGI-F703 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05930210 ↗ |
| Route | Topical | “topical application on target venous leg ulcer, twice daily” NCT04078555 ↗ |